<2-Isopropylmercapto-ethyl>-dimethylamin | 90434-51-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: <2-Isopropylmercapto-ethyl>-dimethylamin
• 英文别名: N,N-dimethyl-2-propan-2-ylsulfanylethanamine
• CAS: 90434-51-8
• 化学式: C₇H₁₇NS
• 分子量: 147.285
• InChiKey: OUXONWCQMZSWQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-丙烷硫醇钠 、 2-氯-N,N-二甲基乙胺 以 乙醇 为溶剂， 反应 1.0h， 生成 <2-Isopropylmercapto-ethyl>-dimethylamin
  参考文献：
  名称：

  Tsatsas,G. et al., Bulletin de la Societe Chimique de France, 1963, p. 2160 - 2162

  摘要：

  DOI：

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• [EN] 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA<br/>[FR] 5-ALKYLTHIO-7-[(4-ARYLBENZYL) AMINO] -1 (2) H-PYRAZOLO [4,3-D] PYRIMIDINES POUR LE TRAITEMENT DU LYMPHOME
  申请人：UNIV PALACKEHO

  公开号：WO2019149295A1

  公开（公告）日：2019-08-08

  The present invention relates to 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidine derivatives of formula I which are effective inhibitors of kinases and exhibit strong antiproliferative and proapoptotic properties on lymphoma cells. This invention further relates to use of said derivatives in the treatment of blood hyperproliferative diseases, such as Non-Hodgkin lymphomas.

  本发明涉及式I的5-烷基硫基-7-[(4-芳基苄基)氨基]-1(2)H-吡唑并[4,3-d]嘧啶衍生物，它们是激酶的有效抑制剂，并在淋巴瘤细胞上表现出强烈的抗增殖和促凋亡特性。本发明还涉及利用这些衍生物治疗血液过度增殖性疾病，如非霍奇金淋巴瘤。
• AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY
  申请人：Shenzhen TargetRx, Inc.

  公开号：US20190152954A1

  公开（公告）日：2019-05-23

  An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.

  一种用于抑制蛋白酪氨酸激酶活性的氨基嘧啶化合物，其制药组合物、制备方法及应用。具体来说，一种由式（I）表示的氨基嘧啶化合物，其中规范中定义了R1、R2、L、Y、R6、W、A、m和n，以及其药用可接受的盐、立体异构体、溶剂化合物、水合物、多形性、前药或同位素变体。该化合物可用于治疗和/或预防蛋白酪氨酸激酶相关疾病，如细胞增殖性疾病、癌症和免疫性疾病。
• Methods for the synthesis of functionalized nucleic acids
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US10280192B2

  公开（公告）日：2019-05-07

  The present application, among other things, provides technologies, e.g., reagents, methods, etc. for preparing oligonucleotides comprising phosphorothiotriesters linkages. In some embodiments, provided methods comprise reacting an H-phosphonate of structure Ia or Ib with a silylating reagent to provide a silyloxyphosphonate, and reacting the silyloxyphosphonate with a thiosulfonate reagent of structure IIa or IIb to provide an oligonucleotide of structure IIIa or IIIb. In some embodiments, provided methods comprise reacting an H-phosphonate of structure Ic with a silylating reagent to provide a silyloxyphosphonate, reacting the silyloxyphosphonate with a bis(thiosulfonate) reagent of structure IVc to provide a phosphorothiotriester comprising a thiosulfonate group of structure Vc, and then reacting the phosphorothiotriester comprising a thiosulfonate group of structure Vc with a nucleophile of structure VIc to provide an oligonucleotide of structure IIIc. In some embodiments, the present application provides a thiosulfonate reagent of structure IIa:

  本申请，除其他外，提供了用于制备包含硫代磷酸酯连接的寡核苷酸的技术，例如试剂、方法等。在一些实施方案中，所提供的方法包括使结构 Ia 或 Ib 的 H-膦酸盐与硅烷化试剂反应以提供硅氧基膦酸盐，并使硅氧基膦酸盐与结构 IIa 或 IIb 的硫代磺酸盐试剂反应以提供结构 IIIa 或 IIIb 的寡核苷酸。在一些实施方案中，所提供的方法包括使结构 Ic 的 H-膦酸盐与硅烷化试剂反应以提供硅氧基膦酸盐，使硅氧基膦酸盐与结构 IVc 的双硫代磺酸酯试剂反应以提供包含结构 Vc 的硫代磺酸酯基团的硫代磷酸酯、然后将包含结构 Vc 的硫代磺酸基团的硫代磷酸酯与结构 VIc 的亲核剂反应，得到结构 IIIc 的寡核苷酸。在某些实施方案中，本申请提供了结构 IIa 的硫代磺酸盐试剂：
• Oligonucleotide compositions and methods thereof
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US10479995B2

  公开（公告）日：2019-11-19

  Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.

  除其他外，本公开涉及选择设计的手性控制寡核苷酸、手性控制寡核苷酸组合物以及制造和使用方法。在一些实施方案中，所提供的手性控制寡核苷酸组合物提供了与参考寡核苷酸组合物不同的核酸聚合物裂解模式。在一些实施方案中，所提供的手性控制寡核苷酸组合物在核酸聚合物的互补序列内提供单位点裂解。在一些实施方案中，手性控制寡核苷酸组合物具有本文所述的任何碱基序列和/或模式或碱基修饰、糖修饰、骨架修饰和/或立体化学，或这些元素的组合。